2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. P2X Receptor
  5. P2X4 Receptor Isoform

P2X4 Receptor

 

P2X4 Receptor Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-136254
    BzATP triethylammonium salt
    		Agonist 99.19%
    BzATP triethylammonium salt acts as a P2X receptor agonist with pEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively. BzATP triethylammonium salt is potent at P2X7 receptors with EC50s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively.
  • HY-101911
    5-BDBD
    		Antagonist 99.94%
    5-BDBD, a potent and selective P2X4 receptor antagonist, inhibits rP2X4R-mediated currents, with an IC50 of 0.75 μM. 5-BDBD completely blocks the basal and acute hyperalgesia induced by nitroglycerin (NTG).
  • HY-130605
    BAY-1797
    		Antagonist 99.76%
    BAY-1797, a chemical probe, is a potent, orally active, and selective P2X4 antagonist, with an IC50 of 211 nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and anti-inflammatory effects.
  • HY-110237
    BX430
    		Antagonist 99.21%
    BX430 is a potent and selective noncompetitive allosteric human P2X4 receptor channels antagonist with an IC50 of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.
  • HY-150270A
    NP-1815-PX sodium
    		Antagonist 99.51%
    NP-1815-PX sodium is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC50 of 0.26 μM against human P2X4 receptors. NP-1815-PX sodium specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX sodium selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX sodium not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX sodium exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX sodium is used in studies related to asthma and inflammatory bowel disease (colitis).
  • HY-101228
    PSB-12054
    		Antagonist 98.94%
    PSB-12054 is a selective P2X4 antagonist with an IC50 of 0.189 μM at human P2X4 receptors. PSB-12054 can be used in the research of neuropathic pain and neurodegenerative diseases.
  • HY-182642
    MRS2339
    		Activator
    MRS2339 is a ribose-modified nucleotide and a nucleotidase-resistant P2 receptor agonist. MRS2339 activates P2X4R. MRS2339 induces ionic currents via P2X receptors, reduces cardiomyocyte cross-sectional area and heart weight/body weight ratio, lacks vasodilatory activity, and extends the lifespan of mice with cardiomyopathy. MRS2339 can be used in research related to heart failure and cardiomyopathy.
  • HY-101910
    PSB-12062
    		Antagonist 98.05%
    PSB-12062 is a potent and selective P2X4 antagonist with an IC50 of 1.38 μM for human P2X4.
  • HY-D0976
    NF279
    		Antagonist 98.5%
    NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC50 value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection.
  • HY-160645
    P2X4 antagonist-1
    		Antagonist 99.89%
    P2X4 antagonist-1 is a P2X4 receptor antagonist with an IC50 of 15 nM. P2X4 antagonist-1 inhibits ATP (HY-B2176)-induced calcium influx. P2X4 antagonist-1 can be used for the research of pain syndromes, endometriosis, cancer.
  • HY-170804
    P2X4 antagonist-3
    		Inhibitor
    P2X4 antagonist-3 (Compound 14c) is a P2X4 antagonist with an IC50 value of 1.2 μM. P2X4 antagonist-3 is promising for research of neuroinflammation, chronic pain, and cancer progression.
  • HY-168474
    P2X4 antagonist-4
    		Antagonist
    P2X4 antagonist-4 (compound 64) is a potent P2X4R antagonist with an IC50 value of 8 µM. P2X4 antagonist-4 blocks the ATP-induced NLRP3 inflammasome activation and release of IL-1β.
  • HY-160677
    P2X4 antagonist-2
    		Antagonist
    P2X4 antagonist-2 is an antagonist for P2X4 with an IC50 of 24 nM.
  • HY-176195
    P2X4-IN-1
    		Inhibitor
    P2X4-IN-1 (Compound 1) is an orally active P2X4 inhibitor. P2X4-IN-1 can be used in the study of prophylaxis disease.